QVIDTVM Management LLC Increases Position in Solventum Co. (NYSE:SOLV)

QVIDTVM Management LLC boosted its holdings in Solventum Co. (NYSE:SOLV) by 389.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 438,217 shares of the company’s stock after purchasing an additional 348,609 shares during the quarter. Solventum comprises 18.5% of QVIDTVM Management LLC’s holdings, making the stock its 3rd largest holding. QVIDTVM Management LLC owned 0.25% of Solventum worth $23,173,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in SOLV. Deseret Mutual Benefit Administrators bought a new position in shares of Solventum during the 2nd quarter worth about $25,000. Hollencrest Capital Management acquired a new position in Solventum during the 2nd quarter worth approximately $25,000. Partnership Wealth Management LLC bought a new position in Solventum in the second quarter worth approximately $26,000. Richard W. Paul & Associates LLC acquired a new stake in Solventum in the second quarter valued at approximately $26,000. Finally, Family Firm Inc. bought a new stake in shares of Solventum during the second quarter valued at approximately $26,000.

Solventum Trading Down 3.3 %

NYSE SOLV opened at $69.95 on Friday. The business has a fifty day moving average price of $61.01. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.31 and a quick ratio of 0.96. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, August 8th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.10. The firm had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.05 billion. The firm’s revenue for the quarter was up .2% on a year-over-year basis. Equities research analysts forecast that Solventum Co. will post 6.38 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on SOLV shares. Morgan Stanley cut their target price on Solventum from $70.00 to $55.00 and set an “equal weight” rating on the stock in a report on Monday, July 15th. Wells Fargo & Company dropped their price objective on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research note on Friday, August 9th. Bank of America reduced their price objective on shares of Solventum from $70.00 to $60.00 and set a “neutral” rating for the company in a report on Tuesday, June 25th. The Goldman Sachs Group upped their target price on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a report on Monday, August 12th. Finally, BTIG Research began coverage on Solventum in a research note on Thursday, September 5th. They set a “neutral” rating for the company. One research analyst has rated the stock with a sell rating and six have assigned a hold rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $58.25.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.